Anti-TIGIT antibodies
AssigneeiTeos Belgium SA
InventorsAnthony Cooper, Christophe Queva, Sofie Denies, Catherine Hoofd, Julia Cuende, Gregory Driessens, Florence Lambolez
Life of this patent
Estimating the term…
Abstract
Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.
Claims15
A method for treating cancer, the method comprising administering to a human patient in need thereof an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an isolated antibody or antigen binding fragment thereof which binds to a human T cell Immunoreceptor with Ig and ITIM domains (TIGIT), wherein the antibody or antigen binding fragment comprises a heavy chain variable domain (VH) comprising a HCDR1, a HCDR2, and a HCDR3, and a light chain variable domain (VL) comprising a LCDR1, a LCDR2 and a LCDR3, wherein:
- the LCDR1 comprises SEQ ID NO:
- 61, the LCDR2 comprises SEQ ID NO:62, and the LCDR3 comprises SEQ ID NO:63;
- and
- the HCDR1 comprises SEQ ID NO:
- 16, the HCDR2 comprises SEQ ID NO:17, and the HCDR3 comprises SEQ ID NO:18.
A method for increasing patient survival in a human patient in need of depletion of T reg cells, the method comprising administering to the human patient an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an isolated antibody or antigen binding fragment thereof which binds to a human T cell Immunoreceptor with Ig and ITIM domains (TIGIT), wherein the antibody or antigen binding fragment comprises a heavy chain variable domain (VH) comprising a HCDR1, a HCDR2, and a HCDR3, and a light chain variable domain (VL) comprising a LCDR1, a LCDR2 and a LCDR3, wherein:
- the LCDR1 comprises SEQ ID NO:
- 61, the LCDR2 comprises SEQ ID NO:62, and the LCDR3 comprises SEQ ID NO:63;
- and
- the HCDR1 comprises SEQ ID NO:
- 16, the HCDR2 comprises SEQ ID NO:17, and the HCDR3 comprises SEQ ID NO:18.
A method for decreasing tumor volume, the method comprising administering to a human patient in need thereof an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an isolated antibody or antigen binding fragment thereof which binds to a human T cell Immunoreceptor with Ig and ITIM domains (TIGIT), wherein the antibody or antigen binding fragment comprises a heavy chain variable domain (VH) comprising a HCDR1, a HCDR2, and a HCDR3, and a light chain variable domain (VL) comprising a LCDR1, a LCDR2 and a LCDR3, wherein:
- the LCDR1 comprises SEQ ID NO:
- 61, the LCDR2 comprises SEQ ID NO:62, and the LCDR3 comprises SEQ ID NO:63;
- and
- the HCDR1 comprises SEQ ID NO:
- 16, the HCDR2 comprises SEQ ID NO:17, and the HCDR3 comprises SEQ ID NO:18.
Dependencies are inferred from the claim text.